MALVERN, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX) (the “Company”), a pharmaceutical company focused on innovative products for acute care settings, today announced that it has adjourned its 2022 Annual Meeting of Shareholders (the “Annual Meeting”), without any business being conducted, due to lack of shareholder participation resulting in a failure to reach required quorum. The Annual Meeting will reconvene at 9:00 a.m. Eastern time on May 18, 2022 and will continue to be held virtually at www.virtualshareholdermeeting.com/BXRX2022.
Baudax Bio Announces Date of Reconvened Annual Meeting of Shareholders
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here